We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA on Thursday approved Genentech’s Rozlytrek (entrectinib) for adults and adolescents who have cancers with a common biomarker — only the third time the agency has approved a cancer treatment on the basis of a biomarker rather than for treatment of a specific tumor. Read More
The drug comes with a boxed warning to alert patients and healthcare providers to the drug’s risk of serious and potentially fatal liver injury. Read More
The drug alongside androgen deprivation therapy provided a median of 40.4 months of metastasis-free survival compared to placebo and ADT’s 18.4 months, a Phase 3 trial showed. Read More
The condition is very serious for type 1 and type 2 diabetes patients and can lead to seizures, comas and even death if not treated properly. Read More